Tuesday, July 2, 2013

$ACHN Notes: OPCO reiterates a Perform Rating - MXIM lowers from Buy

Clinical hold on Achillion drug may not be released,
says Oppenheimer
Jul 2 at 07:50
Profile hits: NONE

      After the FDA placed Achillion's HCV drug sovaprevir on clinical hold
based on its negative interaction with an HIV drug in a study, the firm thinks
the clinical hold may not be released. The firm believes that Achillion will
have trouble finding a partner for sovaprevir, and it reiterates a Perform
rating on the stock.

Achillion downgraded to Hold from Buy at Maxim
Jul 2 at 07:42
Profile hits: QU2 
      Maxim downgraded Achillion after the FDA issued a clinical hold for
sovaprevir. The firm says coming back from clinical holds have historically been
difficult for HCV therapies.

No comments:

Post a Comment